Dataset Information
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Ontology highlight
ABSTRACT:
SUBMITTER: La Mantia L
PROVIDER: S-EPMC6464642 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature
Publications
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
The Cochrane database of systematic reviews 20161124
<h4>Background</h4>Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality of life. As MS cohorts enrolled in diff ...[more]
